
## Latest Updates from CDC's COVID-19 Vaccine Task Force

Evelyn Twentyman, MD MPH ACL Aging and Disability Stakeholder Call January 21<sup>st</sup>, 2022





cdc.gov/coronavirus

# **Key Recommendations from Interim Clinical Considerations**



#### **General Recommendations**

- COVID-19 primary series vaccination is recommended for everyone ages 5 years and older in the United States for the prevention of COVID-19
  - This includes people with underlying medical conditions, and people with & without disabilities
  - People with moderate or severe immunocompromise have additional considerations and need more doses than most people
- In most situations, Pfizer-BioNTech or Moderna COVID-19 vaccines are preferred over the Janssen COVID-19 Vaccine for primary and booster vaccination.



## Recommended COVID-19 Vaccines by Age Group

All people (including people who are moderately or severely immunocompromised)

People who are moderately or severely immunocompromised

Not recommended

Recipient Age	Product	Primary Series	<b>Additional Primary Dose</b>	<b>Booster Dose</b>
5–11 years	Pfizer-BioNTech Orange cap	2 doses separated by 21 days	28 days after primary series dose 2	Not recommended
12–17 years	Pfizer-BioNTech Purple cap or gray cap	2 doses separated by 21 days	28 days after primary series dose 2	5 months after previous dose
18 years and older	Pfizer-BioNTech Purple cap or gray cap	2 doses separated by 21 days	28 days after primary series dose 2	5 months after previous dose
	Moderna	2 doses separated by 28 days	28 days after primary series dose 2	5 months after previous dose
	Janssen	1 dose	Not recommended	2 months after previous dose

### **People with Moderate or Severe Immune Compromise**


- People with immunocompromising conditions or people who take immunosuppressive medications or therapies are at increased risk for severe COVID-19.
- People with immunocompromising conditions may not mount a protective immune response after initial vaccination and protection may wane over time.
- COVID-19 vaccines are not live vaccines and therefore can be safely administered to immunocompromised people.

### **People with Moderate or Severe Immune Compromise**

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge, Wiskott-Aldrich syndromes)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory

## mRNA COVID-19 Vaccines for People with Moderate or Severe Immunocompromise Aged 12 Years and Older

- People with moderate or severe immune compromise at the time of primary vaccination should receive a total of 4 mRNA COVID-19 vaccine doses:
  - 2-dose mRNA COVID-19 Vaccine primary series (preferred over 1 dose Janssen COVID-19 Vaccine)
  - 1 additional primary dose (i.e. third dose) of the same mRNA COVID-19 vaccine
  - 1 booster dose




## Stem Cell Transplant (HCT) and CAR-T-cell recipients

- HCT and CAR-T-cell recipients who received doses of COVID-19 vaccine prior to or during treatment with an HCT or CAR-Tcell therapy should be revaccinated with a primary vaccine series
  - Preferably with an mRNA vaccine (3 doses) regardless of vaccine issued for initial primary vaccination)
  - At least 3 months (12 weeks) after transplant or CAR-T-cell therapy

## Latest Updates to Interim Clinical Considerations




#### Preferential recommendation for mRNA vaccines



- Additional case review and ongoing safety surveillance identified cases (previous and newly occurring) of TTS, including deaths
- No longer in the setting of limited mRNA COVID-19 vaccine supply in the US
- ACIP December 16 Vote: mRNA COVID-19 vaccines are preferred over the Janssen COVID-19 vaccine for the prevention of COVID-19 for those aged ≥18 years

## Additional dose for children 5–11 years with immunocompromise should receive an additional Pfizer-BioNTech primary series dose

- Vaccine effectiveness is lower among patients with immunocompromise<sup>1</sup>
- CDC recommends an additional primary series mRNA vaccine dose in people with immunocompromise aged ≥12 years²
- Approximately 1.4 million children ages 5-17 have an immunocompromsing condition<sup>3</sup>
- Safety findings from VAERS and v-safe during administration of >8 million doses of Pfizer-BioNTech: rare reporting of any serious side effects<sup>4</sup>



## Latest Updates to Mask Recommendations



#### **CDC** mask recommendations

- CDC recommends a layered approach to help slow the spread of COVID-19
- Masks are a critical part of the layered approach
  - Wear a mask with the best fit, protection, and comfort for you
  - In areas of substantial or high community transmission, wear a wellfitting mask indoors in public, regardless of your vaccination status
- Any mask is better than no mask
  - -Take steps to improve how your mask protects you

## **Choosing a mask or respirator**

- Masks and respirators are effective at reducing spread of COVID-19, when worn consistently and correctly
  - Some masks and respirators offer more protection than others
  - Some may be harder to wear consistently than others
- Wear a well-fitted mask or respirator correctly that is comfortable for you and that provides good protection
- Get the latest information about <u>masks and respirators</u> at CDC's website




### Alternative Masks for Special Situations

Clear masks or cloth masks with a clear plastic panel are an alternative type of mask that may be helpful when interacting with certain groups of people, such as:

- People who are deaf or hard of hearing
- Young children or students learning to read
- Students learning a new language
- People with disabilities
- People who need to see the proper shape of the mouth for making appropriate vowel sounds

The FDA cleared for marketing a transparent medical mask. These transparent medical masks should be reserved for use by healthcare workers and patients who require them.





For more information, contact CDC 1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

## Thank you

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

